Exchange: OTC·Updated 03:59 PM EDT
CRLBF logo

CRLBFCresco Labs Inc

$0.77
$0.04
(4.94%)
Today
EarningsAug 6
Mkt Cap$285.67M
Vol554,892.00
News
all
press releases
GTBIF Stock Climbs 17.5% in Three Months: Time to Invest or Cash Out?
Green Thumb has surged 17.5% in three months as regulatory progress, Q1 growth and buybacks lift sentiment, but competition and pricing pressure persist.
Zacks
News Placeholder
More News
News Placeholder
Cannabis Operator Cresco Down 28.5% YTD: How to Play the Stock?
CRLBF is down 28.5% YTD as revenue pressure and competition persist, but retail expansion and improving estimates could shape its next move.
Zacks
News Placeholder
MSOS Hits 2026 High: Which Cannabis Stock Could Light Up Portfolios Ahead Of DEA Hearing?
The cannabis ETF has surged 104% over the past year, outperforming both the North American Marijuana Index and the S&P 500.
Stocktwits
News Placeholder
Cresco Labs Inc. (CRLBF) Upgraded to Buy: Here's Why
Cresco Labs Inc. (CRLBF) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Zacks
News Placeholder
Cresco Labs Inc. (CRLBF) Reports Q1 Loss, Beats Revenue Estimates
Cresco Labs Inc. (CRLBF) delivered earnings and revenue surprises of -33.33% and +1.81%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?
Zacks
News Placeholder
Maravai LifeSciences Holdings, Inc. (MRVI) Tops Q1 Earnings and Revenue Estimates
Maravai LifeSciences (MRVI) delivered earnings and revenue surprises of +121.41% and +20.66%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?
Zacks
News Placeholder
Why Fast-paced Mover Cresco Labs Inc. (CRLBF) Is a Great Choice for Value Investors
Cresco Labs Inc. (CRLBF) could be a great choice for investors looking to buy stocks that have gained strong momentum recently but are still trading at reasonable prices. It is one of the several stocks that made it through our 'Fast-Paced Momentum at a Bargain' screen.
Zacks
News Placeholder
QuidelOrtho (QDEL) Reports Q1 Loss, Tops Revenue Estimates
QuidelOrtho (QDEL) delivered earnings and revenue surprises of -110.81% and +0.28%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?
Zacks
News Placeholder
Cannabis Operator GTBIF Stock Down 17% YTD: Should You Buy the Dip?
Green Thumb has lost 17% YTD as pricing pressure and competition weigh, but steady revenue growth and strong cash flow raise the question: Is the dip worth buying?
Zacks
News Placeholder
Should Cresco Stock Be in Your Portfolio Post Q4 Earnings?
CRLBF faces US pricing pressure despite a Q4 sales beat and a strategic entry into Germany's cannabis market, raising questions about near-term upside.
Zacks
<
1
2
...
>

Advertisement|Remove ads.